Myeloproliferative neoplasms and personalized medicine: the perfect match? (Q43146989)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26628630%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

editorial

0 references

title

Myeloproliferative neoplasms and personalized medicine: the perfect match? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26628630%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

main subject

personalized medicine

1 reference

based on heuristic

inferred from title

author

Jean-Jacques Kiladjian

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26628630%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Claire Harrison

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26628630%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

1 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26628630%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26628630%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26628630%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26628630%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

1493-1494

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26628630%20AND%20SRC:MED&resulttype=core&format=json

A review of the European LeukemiaNet recommendations for the management of CML.

1 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Therapy for myeloproliferative neoplasms: when, which agent, and how?

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Deep molecular response in chronic myeloid leukemia: the new goal of therapy?

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

The spectrum of JAK2-positive myeloproliferative neoplasms

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Some speculations on the myeloproliferative syndromes.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4666324

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

1 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26628630

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3324/HAEMATOL.2015.137182

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26628630%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26628630%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

PubMed publication ID

26628630

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26628630%20AND%20SRC:MED&resulttype=core&format=json